Human Mesenchymal Stem Cells from Placenta (hPSCs) from Ace Therapeutics are human mesenchymal stem cells (hMSC) isolated from placental tissue, specifically from amnion, decidua, or chorion villi. MSC have been shown to differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myocytes, and β-pancreatic islets cells. They can also transdifferentiate into neuronal cells and hepatocytes.

Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

Human iPSC From Adipose Mesenchymal Stromal Cells from Ace Therapeutics are generated using an episomal reprogramming containing a proprietary mix of vectors, containing Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1. The cell line was validated for pluripotency based on colony morphology, alkaline phosphatase expression, and expression of SSEA-4.iPS colonies exhibit classical morphology and growth.

Human Umbilical Cord Blood Mononuclear Cells are a mixture of various cell populations with a single nucleus, including hematopoietic and mesenchymal stem cells, endothelial progenitor cells, lymphocytes, and monocytes. They can be induced to differentiate into neuron cells, osteoblasts, and lymphocytes. Human Umbilical Cord Blood Mononuclear Cells from Ace Therapeutics are isolated from umbilical cord blood. Cells are isolated by density gradient separation and cryopreserved immediately to ensure the best viability. Human Umbilical Cord Blood Mononuclear Cells are quality tested with less than 2% red blood cells.

Human Cord Blood-CD34+ Hematopoietic Stem Cell from Ace Therapeutics are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube and are cryogenically preserved.

Cord blood iPSCs induced with non-viral EBNA1-based episomal vector pEV-SFFV-OS. All cell lines are tested to be free of any transgene vector insertion by PCR analysis and thus are authentic footprint-free iPSCs. These lines have all been passaged long-term (up to P30) without differentiation in optimized human iPSC culture media in the presence of inactivated REF or MEF feeder cells. These lines may have greater propensity to differentiate into Hematopoietic Stem Cells (HSCs) or other mesoderm cells due to epigenetic memory. Great cell model systems for any investigative research work including on iPSCs, HSCs, and disease modeling.Vector: pEV-SFFV-Oct4-2A-Sox2.

Human iPSC Line (Episomal, PBMC) from Ace Therapeutics was derived from human mesenchymal stromal cells (MSCs) by ectopic expression of OCT4, SOX2, KLF4, and L-MYC genes using episomal plasmids.

CD34 is a well-known marker for primitive and bone marrow-derived progenitor cells, especially for hematopoietic and endothelial progenitors. CD34+ progenitor cells are suitable for a series of studies for directed differentiation into more committed types of blood cells and endothelial lineages. Immediately after isolation, the freshly prepared CD34+ progenitor cells are cryopreserved using a serum-free freezing medium. The majority of CD133+ cells also express CD34. Cord blood CD133+ cells are isolated using direct positive immunomagnetic selection for CD133+ cells. Ace Therapeutics offers CD34+ progenitor cells and CD133 cells in a phenotypically undifferentiated state.

The human iPSC line (episomal, CB) from Ace Therapeutics is a type of human induced pluripotent stem cell (iPSC) that was derived from human newborn cord blood (CB) mononuclear cells. The cells were reprogrammed into an embryonic-like pluripotent state using a method involving the introduction of OCT4, SOX2, KLF4, L-MYC, and Lin28 genes through episomal plasmids.